Literature DB >> 21742812

Is azithromycin adequate treatment for asymptomatic rectal chlamydia?

F Drummond1, N Ryder, H Wand, R Guy, P Read, A M McNulty, L Wray, B Donovan.   

Abstract

Rectal chlamydia is a common sexually transmissible infection (STI) in men who have sex with men (MSM) that is predominantly asymptomatic. The recommended treatment of azithromycin 1 g as a single oral dose has not been subject to randomized trials and so its efficacy is unknown. We conducted a retrospective case-note review of all MSM diagnosed at the Sydney Sexual Health Centre with asymptomatic rectal chlamydia in 2009. We identified 116 MSM who received azithromycin; 85 (73%) attended for the recommended re-test at varying times (median 78 days, range 21-372 days). Of the men who returned, 11 (13%) had a persistently positive result; we reviewed behavioural data to classify these men as probable re-infections (6/11) or possible treatment failures (5/11), suggesting an efficacy of 94%. Until a randomized controlled trial (RCT) is conducted, patients with rectal chlamydia should be encouraged to attend for a re-test at 6-12 weeks.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742812     DOI: 10.1258/ijsa.2011.010490

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  15 in total

1.  Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort study.

Authors:  Christine M Khosropour; Julia C Dombrowski; Lindley A Barbee; Lisa E Manhart; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2014-02       Impact factor: 2.830

2.  High prevalence of rectal gonorrhea and Chlamydia infection in women attending a sexually transmitted disease clinic.

Authors:  Jose A Bazan; Patricia Carr Reese; Allahna Esber; Samantha Lahey; Melissa Ervin; John A Davis; Karen Fields; Abigail Norris Turner
Journal:  J Womens Health (Larchmt)       Date:  2015-02-18       Impact factor: 2.681

Review 3.  Hidden in plain sight: chlamydial gastrointestinal infection and its relevance to persistence in human genital infection.

Authors:  Roger G Rank; Laxmi Yeruva
Journal:  Infect Immun       Date:  2014-01-13       Impact factor: 3.441

4.  Differential susceptibilities to azithromycin treatment of chlamydial infection in the gastrointestinal tract and cervix.

Authors:  Laxmi Yeruva; Stepan Melnyk; Nicole Spencer; Anne Bowlin; Roger G Rank
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

5.  Chlamydia trachomatis test-of-cure cannot be based on a single highly sensitive laboratory test taken at least 3 weeks after treatment.

Authors:  Nicole H T M Dukers-Muijrers; Servaas A Morré; Arjen Speksnijder; Marianne A B van der Sande; Christian J P A Hoebe
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

6.  Single Dose of Azithromycin for Treatment of Patients with Asymptomatic Rectal Chlamydia trachomatis.

Authors:  Lou Macaux; Nael Zemali; Julien Jaubert; Yatrika Koumar; Rodolphe Manaquin; Patrice Poubeau; Guillaume Camuset; Patrick Gérardin; Antoine Bertolotti
Journal:  Acta Derm Venereol       Date:  2020-11-04       Impact factor: 3.875

Review 7.  Antibiotic resistance in prevalent bacterial and protozoan sexually transmitted infections.

Authors:  Karl Krupp; Purnima Madhivanan
Journal:  Indian J Sex Transm Dis AIDS       Date:  2015 Jan-Jun

8.  Detection of anorectal and cervicovaginal Chlamydia trachomatis infections following azithromycin treatment: prospective cohort study with multiple time-sequential measures of rRNA, DNA, quantitative load and symptoms.

Authors:  Nicole H T M Dukers-Muijrers; Arjen G C L Speksnijder; Servaas A Morré; Petra F G Wolffs; Marianne A B van der Sande; Antoinette A T P Brink; Ingrid V F van den Broek; Marita I L S Werner; Christian J P A Hoebe
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

9.  Modelling the impact of chlamydia screening on the transmission of HIV among men who have sex with men.

Authors:  Maria Xiridou; Henrike J Vriend; Anna K Lugner; Jacco Wallinga; Johannes S Fennema; Jan M Prins; Suzanne E Geerlings; Bart J A Rijnders; Maria Prins; Henry J C de Vries; Maarten J Postma; Maaike G van Veen; Maarten F Schim van der Loeff; Marianne A B van der Sande
Journal:  BMC Infect Dis       Date:  2013-09-18       Impact factor: 3.090

10.  High co-occurrence of anorectal chlamydia with urogenital chlamydia in women visiting an STI clinic revealed by routine universal testing in an observational study; a recommendation towards a better anorectal chlamydia control in women.

Authors:  Geneviève A F S van Liere; Christian J P A Hoebe; Petra F G Wolffs; Nicole H T M Dukers-Muijrers
Journal:  BMC Infect Dis       Date:  2014-05-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.